Literature DB >> 9336371

Essential hypertension in African Caribbeans associates with a variant of the beta2-adrenoceptor.

P Kotanko1, A Binder, J Tasker, P DeFreitas, S Kamdar, A J Clark, F Skrabal, M Caulfield.   

Abstract

Populations of West African ancestry dwelling in Western communities exhibit greater prevalence of human essential hypertension and higher rates of end-organ damage. The sympathetic nervous system influences cardiac output, vascular tone, renal sodium reabsorption, and renin release and could be implicated in enhanced vascular responsiveness observed in African hypertensives. Such an effect could arise from genetic variants that alter agonist response of alpha-adrenoceptors, leading to enhanced vasoconstriction, or attenuate beta2-adrenoceptor-mediated vasodilatation. Indeed, there is evidence of a blunted vasodilator response to the beta-agonist isoprenaline in African Americans. A variant of the beta2-adrenoceptor gene that encodes glycine rather than arginine at position 16 (Arg16-->Gly) has been shown to confer exaggerated agonist-mediated receptor downregulation, which might attenuate vasodilator response. One hundred thirty-six unrelated hypertensives and 81 unrelated normotensives of African Caribbean origin were identified from primary care on the island of St Vincent. Genomic DNA from these subjects was analyzed for the presence of the Gly16 and Arg16 alleles by using an allele-specific polymerase chain reaction method. We report strong support for association of the prodownregulatory glycine 16 variant of the beta2-adrenoceptor gene with hypertension in African Caribbeans from St Vincent and the Grenadines (chi2=18.9, P=.000014, 1 df). This observation, coupled with reports of attenuated vasodilator responses to beta-agonists among people of West African ancestry, may provide a mechanism for enhanced vascular reactivity and identify a candidate gene for hypertension in this ethnic group.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9336371     DOI: 10.1161/01.hyp.30.4.773

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  20 in total

1.  Polymorphisms 'r us.

Authors:  S C Sealfon
Journal:  Clin Auton Res       Date:  2001-04       Impact factor: 4.435

Review 2.  Genetic polymorphisms of adrenergic receptors.

Authors:  E M Garland; I Biaggioni
Journal:  Clin Auton Res       Date:  2001-04       Impact factor: 4.435

Review 3.  Context-dependent genetic effects in hypertension.

Authors:  S L Kardia
Journal:  Curr Hypertens Rep       Date:  2000-02       Impact factor: 5.369

Review 4.  Cardiac genes and gene databases for cardiovascular disease genetics.

Authors:  K T Tan; A Dempsey; C C Liew
Journal:  Curr Hypertens Rep       Date:  1999 Feb-Mar       Impact factor: 5.369

Review 5.  Beta-adrenoceptor polymorphisms.

Authors:  K Leineweber; R Büscher; H Bruck; O-E Brodde
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-11-28       Impact factor: 3.000

6.  ADRB2 gene variants, dual-energy x-ray absorptiometry body composition, and hypertension in Tobago men of African descent.

Authors:  Tracey Samantha Beason; Clareann H Bunker; Joseph M Zmuda; John W Wilson; Alan L Patrick; Victor W Wheeler; Joel L Weissfeld
Journal:  Metabolism       Date:  2010-08-19       Impact factor: 8.694

7.  Synopsis and data synthesis of genetic association studies in hypertension for the adrenergic receptor family genes: the CUMAGAS-HYPERT database.

Authors:  Georgios D Kitsios; Elias Zintzaras
Journal:  Am J Hypertens       Date:  2009-12-31       Impact factor: 2.689

8.  Beta-2 adrenoreceptor gene polymorphisms and sympathetic outflow in humans.

Authors:  Jens Tank; Karsten Heusser; Andre Diedrich; Dagmara Hering; Friedrich C Luft; Andreas Busjahn; Atakan Aydin; Janusz Limon; Krzysztof Narkiewicz; Jens Jordan
Journal:  Clin Auton Res       Date:  2011-03-30       Impact factor: 4.435

Review 9.  Genetics of hypertension. Therapeutic implications.

Authors:  S O'Byrne; M Caulfield
Journal:  Drugs       Date:  1998-08       Impact factor: 9.546

10.  Polymorphisms of the 5' leader cistron of the human beta2-adrenergic receptor regulate receptor expression.

Authors:  D W McGraw; S L Forbes; L A Kramer; S B Liggett
Journal:  J Clin Invest       Date:  1998-12-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.